the full sample. The MEMS group reported strong satisfaction with the text-messages. Recruitment has been completed, and analyses from the full sample will be ready to present at the meeting. Discussion: Initial results indicate that MEMS is acceptable and may successfully improve motivation in people with schizophrenia-spectrum disorders. However, additional analyses with the full sample are needed to more rigorously test the feasibility and effectiveness of MEMS. (Green, 1993; Green et al, 2000; Heaton et al., 2001; Heinrichs, 1998). While pharmacological treatment is known to have a limited effect on impaired cognition in schizophrenia (Marder, 2006; Rund and Borg, 1999; Elie et al., 2010), a majority of literature has concluded that cognitive remediation(CR) produces small to moderate improvements (McGurk et al., 2007; Wykes et al., 2011). As the smartphone user population continues to increase, the effectiveness of CR based on mobile devices have started to be studied. While CR is effective in improving cognitive deficit, treatment adherence and engagement of participants in the real world setting is known to be poor compared to laboratory setting. Thus, in the current randomized controlled study, we aimed to investigate whether motivational intervention would enhance motivation, treatment adherence and neurocognitive function of individuals with schizophrenia. Methods: All subjects participated in a group-based CR using mobile application (mCR) twice a week for five weeks, and were given opportunity to practice voluntarily outside the treatment sessions. While CR only group participated in usual CR with Q&A sessions, experimental group participated CR sessions integrated with motivational intervention. For motivational enhancement (ME), we employed principles (e.g., goal setting, linking of CR with life goals, etc) of the bridging group (Medalia, Revheim, & Herlands, 2009) along with key aspects of motivational interviewing (e.g., open end questions, affirmation, reflect, and summary). We hypothesized that compared to CR only group, CR+ME group would show higher levels of intrinsic motivation, attendance rate and extra voluntary training hours, and greater improvement in cognitive functions.
S52. WORKING MECHANISMS OF VIRTUAL
In this multi-center randomized controlled trial patients with a psychotic disorder and paranoia were randomized to VR-CBT (n = 58) or treatment as usual (TAU; n = 58). VR-CBT consisted of maximally sixteen 60-minute individual therapy sessions. Paranoia, safety behavior, schematic beliefs, cognitive biases and limitations were assessed at baseline, post-treatment (at three months) and follow-up (at six months). Mixed model analyses were conducted to study treatment effects. Mediation analyses were performed to explore putative working mechanisms by which VR-CBT reduced paranoia.
Results: VR-CBT, but not TAU, led to reductions in jumping to conclusions, attention for threat bias and social cognition problems. Schematic beliefs remained unaffected. The effect of VR-CBT on paranoia was mediated by reductions in safety behavior and social cognition problems. Discussion: VR-CBT affects multiple mechanisms that are associated with paranoid ideation. Although maintaining factors of paranoia are likely to influence each other, targeting safety behavior and social cognitive problems seems effective in breaking the vicious circle of paranoia. 
S53. COMPARISON OF RALOXIFENE AND ISRADIPINE AS AN ADJUNCTIVE TREATMENT IN COGNITIVE DEFICITS OF PATIENTS WITH SCHIZOPHRENIA

Zanjan University of Medical Sciences
Background: Cognitive impairment is the most important feature of schizophrenia that leads to severe social and functional disability. Improving neurocognitive physiopathologic aspect of schizophrenia is a current challenge to identify the pathway to develop goal directed clinical interventions in practice. In the current study we investigated the effect of raloxifine as a selective estrogen modulator and isradipine as a voltage gated L type calcium channel blocker on the enhancement of schizophrenic patients' cognitive deficits. Methods: We designed a double blind randomized, parallel, placebo controlled clinical trials. 60 patients with schizophrenia randomized in 3 specific groups. The first group received isradipine 5 mg, the second raloxifine 60 mg and the third placebo for 6 consequent weeks, in the same shape capsules, 2 times a day, alongside treatment with the conventional antipsychotics. The initial and final lab tests, ECG, as well as cognitive tests in specific domains such as attention, processing speed, executive function and verbal memory were carried out. Results: Our findings, revealed a remarkable association between adjunctive treatment of raloxifine in verbal memory deficits. moreover, isradipine treatment indicated significant improvement relative to placebo in verbal memory as well as attention dysfunction in some variables of the Stroop test. However, no effect was observed in processing speed and executive function deficits. Discussion: The study provides the first evidence to our knowledge, which isradipine as a novel therapy was associated with improvement in verbal
